4 King Street West
Suite 401
Toronto, ON M5H 1B6
Canada
888-223-9165
https://www.thiogenesis.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Patrice P. Rioux M.D., Ph.D. | CEO & Director | 139.01k | N/A | 1951 |
Mr. Brook G. Riggins C.F.A. | CFO, Secretary & Director | 97.35k | 15k | 1966 |
Ms. Mary Jo Bagger | Consultant for Clinical Operations | N/A | N/A | N/A |
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company's lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.
Thiogenesis Therapeutics, Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.